In Response:
In our previous paper (1), we referred to Serakinci's work (2) as an example of human adipose-derived mesenchymal stem cells when they really worked with bone marrow-derived mesenchymal stem cells. We apologize for the confusion that this may have produced among readers.
In response to Dr. Kassem's comments, we would like to clarify that our samples of mesenchymal stem cells were always obtained from appendicitis surgical procedures of patients with no other diseases. In our article, we commented that mesenchymal stem cells reached a senescence phase after 2 months in culture, equivalent to 20 population doublings. After bypassing the senescence phase, all mesenchymal stem cells continued to grow until reaching a crisis phase, 8 months (45 population doublings) after senescence bypass. This growth curve is the rule when working with mesenchymal stem cells. The growth curve reached a plateau for f2 weeks during the senescence phase.
Dr. Kassem cautions about the possible existence of contamination (another cell line) of the samples that became transformed. Because this was a major concern for us, we took some safety checkpoints. Anytime transformation was confirmed, we recultured an aliquot of the original mesenchymal stem cells, frozen at the second initial passing. We then maintained these samples under the culture conditions described in the paper and obtained the same results: transformation among aliquots of samples that had already became tumorigenic and death among aliquots of samples that never did. This fact points to some genetic susceptibility in the spontaneous transformation of mesenchymal stem cells. In addition, we transduced mesenchymal stem cells with retroviral vectors and enhanced green fluorescent protein expression was maintained both in the pretransformed and in the posttransformed mesenchymal stem cells. Another important point was the fact that the same type of malignant transformation was observed in human as well as in murine adipose-derived mesenchymal stem cells. Taken together, these data support the idea that spontaneous transformation of adipose-derived mesenchymal stem cells had occurred in vitro. We also think that the transformation capacity of mesenchymal stem cells is not universal, but there is a still unknown susceptibility in some, but not all, mesenchymal stem cell samples. We agree with Dr. Kassem that this is an exciting field of research, with clear importance when thinking in the clinical use of in vitro-expanded human mesenchymal stem cells.
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